We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Baxter ExactaMix Recalled for Over-Delivery of Ingredients Due to Software Error

Baxter ExactaMix Recalled for Over-Delivery of Ingredients Due to Software Error

March 11, 2024

Due to an overfill feature in mixing medical ingredients potentially leading to an “over-delivery” and adverse health consequences, Baxter Healthcare has recalled for product correction its ExactaMix Pro 1200 and Pro 2400 pharmacy system compounding devices.

The FDA has identified the action as a Class I recall.

The ExactaMix Pro 1200 and Pro 2400 can accommodate up to 12 and 24 ingredients respectively and are primarily used by pharmacies and healthcare professionals to make sterile solutions for pain relief, heart procedures, kidney therapy and nutrition. Due to an error in compounders with software versions 2.0.8 and 2.1.8, using the “Use Some Overfill” feature could result in redundant ingredient delivery to the automated devices.

To read the whole story, click here to subscribe.

Related Topics

Devices Regulatory Affairs

    Upcoming Events

    • 13Mar

      Unmatched Expertise & Guidance When Navigating EACs & DMCs

    • 14Mar

      From QSR to QMSR: Meeting FDA’s New Requirements

    • 21Mar

      FDA as a Development Partner: A New Approach to Product Review Meetings

    • 28Mar

      The Inflation Reduction Act (IRA): How Will It Impact Drug Development?

    • 11Apr

      Integrating Regulatory Intelligence into Supplier Management

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Diabetes Diagnosis and Management Could be Improved with Digital Health Tools

    • Biden Touts All 10 Drugs’ Participation in IRA Price Negotiation Program

    • FDA Committee Gives Thumbs Up to Breast Cancer Lumpectomy Drug-Device Combo

    • FDA Clears First OTC Continuous Glucose Monitor

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing